---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-287073"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2024-12-31T23:59:59+00:00"
generated_at: "2026-05-28T21:47:24.473372+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics acquires Nova Pharmaceuticals in merger; issues Series B Preferred and closes $2.885M PIPE

## Summary
- Acquisition closed Dec 30; Galera issued 119,318 shares of Series B Non-Voting Convertible Preferred (1,000-to-1 conversion).
- Raised $2.885M via private placement of 44,111,260 common shares and pre-funded warrants.
- Three directors resigned (Powell, West, Cunningham); Nancy Chang and Michael Friedman appointed as Class I directors.
- Board reduced from six to five; stockholders to vote on Series B conversion and reverse split within 12-18 months.
- 90-day lock-up on shares from merger for certain securityholders and directors/officers.

## SEC filing metadata
- accession: 0001193125-24-287073
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2024-12-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/0001193125-24-287073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/d899535d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-287073
- JSON: https://secwatch.observer/filing/0001193125-24-287073.json
- Plain text: https://secwatch.observer/filing/0001193125-24-287073.txt

## Key facts
- Governance Changes
  Galera Therapeutics, Inc.: Galera intends to file a Certificate of Elimination to eliminate the Series A Junior Participating Preferred Stock designation, returning those shares to authorized but unissued preferred stock (effective 2024-12-31).
  - Change: charter amendment
  - Effective: 2024-12-31
  source text: Galera intends to file a Certificate of Elimination eliminating from its Certificate of Incorporation, as amended, the designation of certain shares of its preferred stock as Series A Junior Participating Preferred Stock, which had been designated for potential use in connection with the Rights Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/0001193125-24-287073-index.htm
- M&A Transactions
  Galera Therapeutics, Inc. completed an acquisition involving Nova Pharmaceuticals, Inc. for 119,318.285 shares of preferred stock, par value $0.001 per share, designated as Series B Non-Voting Convertible Preferred Stock (closed 2024-12-30).
  - Action: acquisition
  - Counterparty: Nova Pharmaceuticals, Inc.
  - Consideration: 119,318.285 shares of preferred stock, par value $0.001 per share, designated as Series B Non-Voting Convertible Preferred Stock
  - Closing: 2024-12-30
  source text: (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share GRTX OTC Pink Market Series A Junior Participating Preferred Stock (Purchase Rights) N/A OTC Pink Market Indicate by check mark whether the registrant is an
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/0001193125-24-287073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.